Mumps clinical trials
The registry lists 46 studies for Mumps across more than 10 countries. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-24.
Status
- Completed
- 34
- Active, not recruiting
- 4
- Recruiting
- 4
- Not yet recruiting
- 2
- Withdrawn
- 1
- Status unknown
- 1
Phase
- Phase 3
- 21
- Phase 4
- 10
- Phase 2
- 6
- Phase 1
- 2
Where
- China
- 12
- United States
- 12
- Taiwan
- 5
- Germany
- 5
- Puerto Rico
- 5
- Finland
- 4
Who runs them
GlaxoSmithKline (17) · Institute of Medical Biology, Chinese Academy of Medical Sciences (3) · Sinovac (Dalian) Vaccine Technology Co., Ltd. (3) · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (3) · Merck Sharp & Dohme LLC (3) · Sanofi Pasteur, a Sanofi Company (2) · Sinovac Research and Development Co., Ltd. (1) · Children's Mercy Hospital Kansas City (1)
Studies
Recruiting first, then most recently updated. Showing 46 of 46 — search for more.
- Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation PatientsRecruitingNCT07195032Phase 41 country
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of AgeNot yet recruitingNCT07742644Phase 36 countries
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of AgeRecruitingNCT07406360Phase 31 country
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT073589101 country
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L VaccinesNot yet recruitingNCT073388511 country
- Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster VaccinationRecruitingNCT05894395Phase 31 country
- Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMRCompletedNCT02325310Phase 41 country
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 MonthsCompletedNCT06399003Phase 31 country
- A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy AdultsActive, not recruitingNCT06967181Phase 11 country
- Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)CompletedNCT06331702Phase 41 country
- A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of AgeCompletedNCT05630846Phase 25 countries
- The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School StudentsActive, not recruitingNCT06208683Phase 41 country
- Phase II/III of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Healthy Children Aged 5-11Active, not recruitingNCT04591405Phase 2/31 country
- Phase II of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese InfantsActive, not recruitingNCT03133923Phase 21 country
- A Phase I, Safety Study of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese ChildrenCompletedNCT01712906Phase 11 country
- The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella VaccineStatus unknownNCT05279248Phase 41 country
- Safety Study of Live Attenuated Mumps Vaccines in Junior High School Students Under 14 Years OldCompletedNCT051451661 country
- Measles, Mumps, and Rubella (MMR) Immunity in College StudentsCompletedNCT009628191 country
- Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy InfantsCompletedNCT05065177Phase 31 country
- Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps VaccineCompletedNCT04364399Phase 41 country
- Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of AgeCompletedNCT02184572Phase 35 countries
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of LifeCompletedNCT01681992Phase 37 countries
- Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) VaccineCompletedNCT02880865Phase 41 country
- Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of AgeCompletedNCT00861744Phase 22 countries
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of AgeCompletedNCT01621802Phase 33 countries
- Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)CompletedNCT00092430Phase 3
- Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)CompletedNCT01536405Phase 3
- Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136CompletedNCT00751348Phase 31 country
- Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTMCompletedNCT00969436Phase 31 country
- Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and OlderCompletedNCT02058563Phase 33 countries
- Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy InfantsCompletedNCT02692599Phase 31 country
- Observational Study to Assess Protection to Mumps in Children Received One-dose Mumps-containing VaccineCompletedNCT029019901 country
- Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™CompletedNCT00353288Phase 23 countries
- Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™CompletedNCT00352898Phase 22 countries
- Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox DiseasesCompletedNCT00127010Phase 33 countries
- Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox DiseasesCompletedNCT00127023Phase 31 country
- Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox DiseasesCompletedNCT00126997Phase 44 countries
- Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined VaccineCompletedNCT00406211Phase 32 countries
- Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose PresentationsCompletedNCT01777529Phase 41 country
- Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.CompletedNCT01991899Phase 31 country
- A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)CompletedNCT00092391Phase 3
- Making Decisions About the Measles-Mumps-Rubella VaccineCompletedNCT01369394Not applicable1 country
- Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese ToddlersCompletedNCT01188343Phase 31 country
- Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined VaccineCompletedNCT00313950Phase 41 country
- Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the PhilippinesWithdrawnNCT01738841
- Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella)CompletedNCT018744571 country